Pandorum Technologies, a biotechnology company operating from the US and India, has secured $18.0 million in its latest funding round. The company specializes in Tissue Engineering and Regenerative Medicine, leveraging a distinct synergy of life science, engineering, and clinical competences. Pandorum has developed a proprietary technology platform that combines therapeutic exosomes derived from clinical-grade human stem cells with anti-inflammatory, anti-fibrotic properties and biomaterials with tissue-mimetic properties. This platform is designed to promote efficient regeneration of human tissues, including the cornea, liver, and lung.
The company's innovative approach aims to address unmet clinical needs for millions globally. Pandorum's efforts have been supported by various government grants, including BIG and SBIRI, and it has previously raised capital from marquee investors and venture capitalists. The company prides itself on a world-class team of scientists, engineers, clinicians, and key opinion leaders who are deeply engaged in product development and clinical translation.
Pandorum's commitment to clinical translation is further bolstered by collaborations with renowned medical institutions such as Northwestern Medicine in Chicago, US, the Medical University of South Carolina in Charleston, US, and Dr. Shroff’s Charity Eye Hospital in New Delhi, India. The company is also recognized as an Endless Frontier Labs (EFL) start-up, part of NYU Stern School of Business, Life Sciences Cohort - 2023. The newly raised capital will be deployed to accelerate research and development initiatives, expand clinical translation efforts, and scale operations to bring its regenerative medicine solutions to patients.
This investment underscores confidence in Pandorum's mission to make Regenerative Medicine an efficacious and scalable mainstream reality. The company remains dedicated to addressing the suffering of millions affected by various diseases through its advanced tissue regeneration technologies.
